ATE475428T1 - Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen - Google Patents

Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen

Info

Publication number
ATE475428T1
ATE475428T1 AT01933358T AT01933358T ATE475428T1 AT E475428 T1 ATE475428 T1 AT E475428T1 AT 01933358 T AT01933358 T AT 01933358T AT 01933358 T AT01933358 T AT 01933358T AT E475428 T1 ATE475428 T1 AT E475428T1
Authority
AT
Austria
Prior art keywords
cells
autoreactive
blocking
destruction
polypeptide
Prior art date
Application number
AT01933358T
Other languages
German (de)
English (en)
Inventor
Yang Liu
Pan Zheng
Xue-Feng Bai
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Application granted granted Critical
Publication of ATE475428T1 publication Critical patent/ATE475428T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT01933358T 2000-03-29 2001-03-29 Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen ATE475428T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19281400P 2000-03-29 2000-03-29
PCT/US2001/040390 WO2001072325A1 (en) 2000-03-29 2001-03-29 Methods of blocking tissue destruction by autoreactive t cells

Publications (1)

Publication Number Publication Date
ATE475428T1 true ATE475428T1 (de) 2010-08-15

Family

ID=22711138

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01933358T ATE475428T1 (de) 2000-03-29 2001-03-29 Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen

Country Status (8)

Country Link
EP (1) EP1267909B1 (https=)
JP (1) JP2004500110A (https=)
AT (1) ATE475428T1 (https=)
AU (2) AU2001259792B2 (https=)
CA (1) CA2404340C (https=)
DE (1) DE60142684D1 (https=)
DK (1) DK1267909T3 (https=)
WO (1) WO2001072325A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030106084A1 (en) 2000-03-29 2003-06-05 Yang Liu Methods of blocking tissue destruction by autoreactive T cells
US8808697B2 (en) * 2010-04-28 2014-08-19 Oncoimmune, Inc. Methods of use of soluble CD24 for therapy of rheumatoid arthritis
US20150140019A1 (en) * 2012-07-13 2015-05-21 The Trustees Of The University Of Pennsylvania Compositions and Methods for Regulating CAR T Cells
GB201300684D0 (en) 2013-01-15 2013-02-27 Apitope Int Nv Peptide
SG10201913782UA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cll-1 chimeric antigen receptor
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
US20190119353A1 (en) * 2014-11-06 2019-04-25 Children's Research Institute, Children's National Medical Center Immunotherapeutics for cancer and autoimmune diseases
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
EP3334449B1 (en) * 2015-08-10 2021-09-29 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
EP3411062B1 (en) * 2016-02-02 2020-11-25 Oncoimmune Inc. Use of cd24 proteins for treating leptin-deficient conditions
JP2020510020A (ja) * 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
EP3624838B1 (en) * 2017-05-15 2023-01-25 Oncoimmune, Inc. Methods of use of soluble cd24 for neuroprotection and remyelination
TWI890660B (zh) 2018-06-13 2025-07-21 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途

Also Published As

Publication number Publication date
CA2404340A1 (en) 2001-10-04
DK1267909T3 (da) 2010-11-08
AU2001259792B2 (en) 2005-12-22
WO2001072325A1 (en) 2001-10-04
WO2001072325A9 (en) 2003-02-20
EP1267909A1 (en) 2003-01-02
AU5979201A (en) 2001-10-08
JP2004500110A (ja) 2004-01-08
EP1267909B1 (en) 2010-07-28
EP1267909A4 (en) 2006-05-03
DE60142684D1 (de) 2010-09-09
CA2404340C (en) 2012-10-16

Similar Documents

Publication Publication Date Title
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
ATE475428T1 (de) Verfahren zur blockierung der zerstörung von gewebe mittels autoreaktiver t-zellen
EP0751992A4 (en) VASCULAR ENDOTHELIAL GROWTH FACTOR 2
JPH04507195A (ja) 腫瘍壊死因子結合リガンド
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
DE69932084D1 (de) Antikörperfragmente zur lokalen Behandlung von Augenerkrankungen
EP1140175A4 (en) ANTIBODIES AGAINST SHORTENED VEGF-D AND THEIR USE
KR927003816A (ko) Cd3에 대한 항체
EP0837696A4 (en) IMPROVED DELIVERY OF DIAGNOSTIC AND THERAPEUTIC SUBSTANCES AT ONE DESTINATION
DE69309472D1 (de) Fusionsproteine von monomeren und dimeren von antikörperfragmenten
DE602004032328D1 (de) Medizinische verwendung von anti-cs1 antikörpern
FI973120A0 (fi) Ihmisen gp39:n eri epitoopeille spesifisiä monoklonaalisia vasta-aineita ja menetelmiä niiden käyttämiseksi diagnosoinnissa ja terapiassa
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
DK161015C (da) Blanding til anvendelse ved ekstern paavisning og lokalisering af en blodprop
DE69632465D1 (de) Cdr-transplantierte antikörper gegen "tissue factor" und verfahren zur deren verwendung
DE68925226D1 (de) Monoklonale Antikörper
EP1003552A4 (en) ANTIBODIES DIRECTED AGAINST LO-CD2a AND USE THEREOF TO INHIBIT THE ACTIVATION AND PROLIFERATION OF T-LYMPHOCYTES
ES2102360T3 (es) Proteina de la superficie celular asociada a linfocitos.
Trune et al. Failure of elevated heat shock protein 70 antibodies to alter cochlear function in mice
DE69638024D1 (de) Melanoma antigene p15 und deren anwendung in diagnostischen und therapeutischen verfahren
AR003941A1 (es) Anticuerpos monoclonales humanos neutralizadores de hiv-1
Moolten et al. Induction of antibodies against carcinogenic polycyclic aromatic hydrocarbons
ATE205531T1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
EA199800352A1 (ru) ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА
DK1039931T3 (da) Multivalente rekombinante antistoffer til at behandle HRV infektioner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties